Your search returned 17 results.

Results
	1.	Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41. MedStar authors: Swain, Sandra M PMID: 36944848 Year: 2023 Citation: Breast Cancer Research & Treatment. 199(2):243-252, 2023 Jun. Department: Associate Dean for Research Development MedStar Health Medline publication type: Journal Article Randomized Controlled Trial Form of publication: Journal Article All authors: Azar CA, Baez-Diaz L, Bandos H, Bear HD, Boileau JF, Brufsky AM, Geyer CE Jr Hassan S, Magrinat GC, Mamounas EP, Paik S, Rastogi P, Sarwar S, Shibata HR, Suga JM, Swain SM, Tang G, Wolmark N, Yothers G DOI: https://dx.doi.org/10.1007/s10549-023-06881-8 Add to cart (remove)
	2.	The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40. MedStar authors: Swain, Sandra M PMID: 27864694 Year: 2016 Citation: Annals of Surgical Oncology. 24(7):1853-1860, 2017 Jul Institution: Washington Cancer Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Adams PT, Baez-Diaz L, Bear HD, Brufsky AM, Costantino JP, Fehrenbacher L, Gaur R, Geyer CE Jr, Gross HM, Kidwell KM, Mamounas EP, Margolese RG, Mehta RS, Paik S, Rastogi P, Robidoux A, Senecal FM, Swain SM, Tang G, Wolmark N, Young JA, Zoon CK DOI: https://dx.doi.org/10.1245/s10434-016-5662-9 Add to cart (remove)
	3.	Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). MedStar authors: Swain, Sandra M PMID: 24129974 Year: 2013 Citation: Breast Cancer Research & Treatment. 142(1):89-99, 2013 Nov. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Amadori D, Baselga J, Clark E, Knott A, Miles D, Ross G, Semiglazov V, Sunpaweravong P, Swain SM DOI: http://dx.doi.org/10.1007/s10549-013-2710-z Add to cart (remove)
	4.	Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. MedStar authors: Swain, Sandra M PMID: 23475636 Year: 2013 Citation: Oncologist. 18(3):257-64, 2013. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Amadori D, Baselga J, Benyunes MC, Clark E, Cortes J, Ewer MS, Knott A, Miles D, Ross G, Swain SM DOI: http://dx.doi.org/10.1634/theoncologist.2012-0448 Add to cart (remove)
	5.	Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. MedStar authors: Swain, Sandra M PMID: 25693012 Year: 2015 Citation: New England Journal of Medicine. 372(8):724-34, 2015 Feb 19. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Baselga J, Benyunes MC, Campone M, Ciruelos E, Clark E, CLEOPATRA Study Group, Cortes J, Ferrero JM, Heeson S, Kim SB, Ro J, Ross G, Schneeweiss A, Semiglazov V, Swain SM DOI: http://dx.doi.org/10.1056/NEJMoa1413513 Add to cart (remove)
	6.	Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. MedStar authors: Swain, Sandra M PMID: 24869931 Year: 2014 Citation: Oncologist. 19(7):693-701, 2014 Jul. Institution: Washington Cancer Institute Form of publication: Journal Article All authors: Baselga J, Chan V, Clark E, Im SA, Im YH, Knott A, Miles D, Ross G, Swain SM DOI: http://dx.doi.org/10.1634/theoncologist.2014-0033 Add to cart (remove)
	7.	HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane. MedStar authors: Kurian, Shweta Mohebtash, Mahsa Ottaviano, Yvonne Rao, Suman Swain, Sandra M PMID: 36280642 Year: 2022 Citation: Breast Cancer Research & Treatment. 196(3):571-581, 2022 Dec. Institution: MedStar Franklin Square Medical Center Department: Associate Dean for Research Development Hematology/Oncology MedStar Health Medline publication type: Clinical Trial, Phase II Journal Article Randomized Controlled Trial Form of publication: Journal Article All authors: Dilawari A, Graham D, Isaacs C, Kurian S, Lynce F, Mainor C, McNamara D, Mohebtash M, Ottaviano Y, Pohlmann PR, Rao S, Swain SM, Swanson N, Tan M, Warren R, Wu T DOI: https://dx.doi.org/10.1007/s10549-022-06743-9 Add to cart (remove)
	8.	HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens. MedStar authors: Swain, Sandra M PMID: 27692565 Year: 2017 Citation: Clinical Breast Cancer. 17(1):76-78, 2017 Feb Institution: Washington Cancer Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Gao JJ, Pohlmann PR, Swain SM, Tan M DOI: https://dx.doi.org/10.1016/j.clbc.2016.08.005 Add to cart (remove)
	9.	Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30. MedStar authors: McCarron, Edward C Swain, Sandra M PMID: 28954297 Year: 2018 Citation: Journal of the National Cancer Institute. 110(2), 2018 Feb 01 Institution: MedStar Franklin Square Medical Center Washington Cancer Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Bandos H, Brufsky AM, Fehrenbacher L, Ganz PA, Julian TB, Margolese RG, McCarron EC, Melnikow J, Rivera DR, Sturtz K, Swain SM, Wade JL 3rd DOI: https://dx.doi.org/10.1093/jnci/djx162 Add to cart (remove)
	10.	Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. MedStar authors: Swain, Sandra M PMID: 23868905 Year: 2013 Citation: Annals of Oncology. 24(10):2630-5, 2013 Oct. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Baselga J, Clark E, Cortes J, Im SA, Im YH, Knott A, Pivot X, Ross G, Swain SM DOI: http://dx.doi.org/10.1093/annonc/mdt274 Add to cart (remove)
	11.	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. MedStar authors: Swain, Sandra M PMID: 23602601 Year: 2013 Citation: Lancet Oncology. 14(6):461-71, 2013 May. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Baselga J, Benyunes MC, Campone M, Ciruelos E, Clark E, Cortes J, Ferrero JM, Kim SB, Knott A, Ro J, Ross G, Schneeweiss A, Semiglazov V, Swain SM DOI: http://dx.doi.org/10.1016/S1470-2045(13)70130-X Add to cart (remove)
	12.	Avastin withdrawal symptoms. MedStar authors: Lynce, Filipa Swain, Sandra M PMID: 22263961 Citation: Expert Opinion on Pharmacotherapy. 13(3):293-8, 2012 Feb. Institution: Washington Cancer Institute Medline publication type: Editorial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Lynce F, Swain SM DOI: http://dx.doi.org/10.1517/14656566.2012.652088 Add to cart (remove)
	13.	Bevacizumab added to neoadjuvant chemotherapy for breast cancer. MedStar authors: Swain, Sandra M PMID: 22276821 Year: 2012 Citation: New England Journal of Medicine. 366(4):310-20, 2012 Jan 26. Institution: Washington Cancer Institute Medline publication type: Journal Article Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Form of publication: Journal Article All authors: Adams PT, Atkins JN, Baez-Diaz L, Bear HD, Brufsky AM, Costantino JP, Fehrenbacher L, Gaur R, Geyer CE Jr, Gross HM, Mamounas EP, Margolese RG, Mehta RS, Rastogi P, Robidoux A, Senecal FM, Swain SM, Tang G, Wolmark N, Young JA DOI: http://dx.doi.org/10.1056/NEJMoa1111097 Add to cart (remove)
	14.	Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. MedStar authors: Swain, Sandra M PMID: 34890214 Year: 2022 Citation: Journal of Clinical Oncology. 40(5):438-448, 2022 02 10. Department: Associate Dean for Research Development Medline publication type: Journal Article Form of publication: Journal Article All authors: Barrios C, Bonnefoi H, Boulet T, De Laurentiis M, Ellis PA, Fehrenbacher L, Gianni L, Gralow J, Harbeck N, Huang CS, Im SA, Im YH, Ito Y, Krop IE, Liu H, Macharia H, Nowecki Z, Shah J, Song C, Swain SM, Toi M, Trask P, Winer EP DOI: https://dx.doi.org/10.1200/JCO.21.00896 Add to cart (remove)
	15.	Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. MedStar authors: Swain, Sandra M PMID: 24095300 Year: 2013 Citation: Lancet Oncology. 14(12):1183-92, 2013 Nov. Institution: Washington Cancer Institute Medline publication type: Clinical Trial, Phase III Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Atkins JN, Azar CA, Baez-Diaz L, Bandos H, Bear HD, Brufsky AM, Costantino JP, Farrar WB, Fehrenbacher L, Geyer CE Jr, Mamounas EP, Margolese RG, Paik S, Rastogi P, Robidoux A, Sarwar S, Shibata HR, Swain SM, Tang G, Wolmark N DOI: http://dx.doi.org/10.1016/S1470-2045(13)70411-X Add to cart (remove)
	16.	Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2. MedStar authors: Swain, Sandra M Zapas, John L PMID: 29072977 Year: 2017 Citation: Journal of Clinical Oncology. 35(35):3942-3948, 2017 Dec 10 Institution: Washington Cancer Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Atkins JN, Biggs DD, Brufsky AM, Cecchini RS, Fehrenbacher L, Flynn PJ, Ganz PA, Geyer CE Jr, Gross HM, Jeong JH, Mamounas EP, Polikoff J, Rastogi P, Romond EH, Seay TE, Swain SM, Wade JL 3rd, Wahl TA, Wolmark N, Zapas JL DOI: https://dx.doi.org/10.1200/JCO.2017.74.1165 Add to cart (remove)
	17.	Phase I trial of dasatinib and ixabepilone in patients with solid tumors. MedStar authors: Herbolsheimer, Pia M Jelinek, James S Kapoor, R Perry, David J Smith, Karen L Swain, Sandra M Verma, Nitin Veytsman, Irina PMID: 22392508 Citation: Investigational New Drugs. 31(1):92-8, 2013 Feb. Institution: MedStar Washington Hospital Center Washington Cancer Institute Department: Radiology Medline publication type: Clinical Trial, Phase I Journal Article Research Support, Non-U.S. Gov't Form of publication: Journal Article All authors: Herbolsheimer P, Jelinek J, Kapoor R, Perry D, Smith KL, Swain SM, Verma N, Veytsman I DOI: http://dx.doi.org/10.1007/s10637-012-9805-y Add to cart (remove)

Powered by Koha